Bapineuzumab for mild to moderate Alzheimer’s disease: a meta-analysis of randomized controlled trials View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-04-04

AUTHORS

Abdelrahman Ibrahim Abushouk, Ahmed Elmaraezy, Amro Aglan, Reham Salama, Samar Fouda, Rana Fouda, Ammar M. AlSafadi

ABSTRACT

BackgroundAlzheimer’s disease (AD) is a globally prevalent neurodegenerative condition, clinically characterized by progressive memory loss and gradual impairment of cognitive functions. Bapineuzumab is a fully humanized monoclonal antibody that binds to neurotoxic amyloid proteins in the brain, enhancing their clearance. We performed this systematic review and meta-analysis to evaluate the safety and efficacy of bapineuzumab in patients with mild to moderate Alzheimer’s disease.MethodsWe performed a web-based literature search of PubMed, Ovid, EBSCO, Scopus, Embase, Cochrane CENTRAL, and web of science using the relevant keywords. Data were extracted from eligible records and pooled as mean difference (MD) or risk ratio (RR) values with their 95% confidence interval (CI), using Review Manager software (version 5.3 for windows). Heterogeneity was measured by Chi-square and I-square tests.ResultThe pooled effect estimate from six randomized clinical trials (n = 2380) showed that bapineuzumab significantly reduced the cerebrospinal fluid concentration of phosphorylated tau proteins (Standardized MD = −5.53, 95% CI [−8.29, −2.76]). However, the bapineuzumab group was not superior to the placebo group in terms of change from baseline in Alzheimer’s disease assessment scale (ADAS)-Cog11 (MD = 0.14, 95% CI [−0.72, 0.99]), disability assessment for dementia (DAD) scale (MD = 1.35, 95% CI [−1.74, 4.43]), and mini-mental state examination (MMSE) scores (MD = 0.08, 95% CI [−0.31, 0.47]). Regarding safety, bapineuzumab increased the risk of serious treatment-emergent adverse events (RR = 1.18, 95% CI [1.02, 1.37]) and cerebral vasogenic edema (RR = 40.88, 95% CI [11.94, 135.95]). All bapineuzumab doses (0.15, 0.5, 1, and 2 mg/kg) were similar to placebo in terms of change from baseline in ADAS-cog11, DAD, and MMSE scores, except for the 0.15 mg/kg dose, which caused a significant worsening on the ADAS-cog11 scale (MD = 5.6, 95% CI [0.22, 10.98]).ConclusionsConsidering the lack of clinical efficacy, combined with the significant association with serious adverse events, bapineuzumab should not be used to treat patients with mild to moderate AD. Future studies should investigate the effect of combining bapineuzumab with other therapeutic strategies and reevaluate the efficacy of targeting amyloid β proteins in AD therapy. More... »

PAGES

66

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12883-017-0850-1

DOI

http://dx.doi.org/10.1186/s12883-017-0850-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1084512801

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28376794


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1109", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Neurosciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Alzheimer Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Outcome Assessment, Health Care", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "NovaMed Medical Research Association, Cairo, Egypt", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Faculty of Medicine, Ain Shams University, Cairo, Egypt", 
            "NovaMed Medical Research Association, Cairo, Egypt"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Abushouk", 
        "givenName": "Abdelrahman Ibrahim", 
        "id": "sg:person.01071425357.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01071425357.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Faculty of Medicine, Al-Azhar University, Cairo, Egypt", 
          "id": "http://www.grid.ac/institutes/grid.411303.4", 
          "name": [
            "NovaMed Medical Research Association, Cairo, Egypt", 
            "Faculty of Medicine, Al-Azhar University, Cairo, Egypt"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Elmaraezy", 
        "givenName": "Ahmed", 
        "id": "sg:person.013206550571.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013206550571.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Faculty of Medicine, Tanta University, Tanta, Egypt", 
          "id": "http://www.grid.ac/institutes/grid.412258.8", 
          "name": [
            "Faculty of Medicine, Tanta University, Tanta, Egypt"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Aglan", 
        "givenName": "Amro", 
        "id": "sg:person.012124155033.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012124155033.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Faculty of Medicine, Benha University, Qaluobia, Egypt", 
          "id": "http://www.grid.ac/institutes/grid.411660.4", 
          "name": [
            "Faculty of Medicine, Benha University, Qaluobia, Egypt"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Salama", 
        "givenName": "Reham", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Faculty of Medicine, Zagazig University, Elsharkia, Egypt", 
          "id": "http://www.grid.ac/institutes/grid.31451.32", 
          "name": [
            "Faculty of Medicine, Zagazig University, Elsharkia, Egypt"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fouda", 
        "givenName": "Samar", 
        "id": "sg:person.01365162611.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01365162611.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Faculty of Medicine, Zagazig University, Elsharkia, Egypt", 
          "id": "http://www.grid.ac/institutes/grid.31451.32", 
          "name": [
            "Faculty of Medicine, Zagazig University, Elsharkia, Egypt"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fouda", 
        "givenName": "Rana", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Faculty of Medicine, Damascus University, Damascus, Syria", 
          "id": "http://www.grid.ac/institutes/grid.8192.2", 
          "name": [
            "Faculty of Medicine, Damascus University, Damascus, Syria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "AlSafadi", 
        "givenName": "Ammar M.", 
        "id": "sg:person.015112057033.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015112057033.82"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/78682", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039144595", 
          "https://doi.org/10.1038/78682"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm1782", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013028078", 
          "https://doi.org/10.1038/nm1782"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-04-04", 
    "datePublishedReg": "2017-04-04", 
    "description": "BackgroundAlzheimer\u2019s disease (AD) is a globally prevalent neurodegenerative condition, clinically characterized by progressive memory loss and gradual impairment of cognitive functions. Bapineuzumab is a fully humanized monoclonal antibody that binds to neurotoxic amyloid proteins in the brain, enhancing their clearance. We performed this systematic review and meta-analysis to evaluate the safety and efficacy of bapineuzumab in patients with mild to moderate Alzheimer\u2019s disease.MethodsWe performed a web-based literature search of PubMed, Ovid, EBSCO, Scopus, Embase, Cochrane CENTRAL, and web of science using the relevant keywords. Data were extracted from eligible records and pooled as mean difference (MD) or risk ratio (RR) values with their 95% confidence interval (CI), using Review Manager software (version 5.3 for windows). Heterogeneity was measured by Chi-square and I-square tests.ResultThe pooled effect estimate from six randomized clinical trials (n\u00a0=\u00a02380) showed that bapineuzumab significantly reduced the cerebrospinal fluid concentration of phosphorylated tau proteins (Standardized MD\u00a0=\u00a0\u22125.53, 95% CI [\u22128.29, \u22122.76]). However, the bapineuzumab group was not superior to the placebo group in terms of change from baseline in Alzheimer\u2019s disease assessment scale (ADAS)-Cog11 (MD\u00a0=\u00a00.14, 95% CI [\u22120.72, 0.99]), disability assessment for dementia (DAD) scale (MD\u00a0=\u00a01.35, 95% CI [\u22121.74, 4.43]), and mini-mental state examination (MMSE) scores (MD\u00a0=\u00a00.08, 95% CI [\u22120.31, 0.47]). Regarding safety, bapineuzumab increased the risk of serious treatment-emergent adverse events (RR\u00a0=\u00a01.18, 95% CI [1.02, 1.37]) and cerebral vasogenic edema (RR\u00a0=\u00a040.88, 95% CI [11.94, 135.95]). All bapineuzumab doses (0.15, 0.5, 1, and 2\u00a0mg/kg) were similar to placebo in terms of change from baseline in ADAS-cog11, DAD, and MMSE scores, except for the 0.15\u00a0mg/kg dose, which caused a significant worsening on the ADAS-cog11 scale (MD\u00a0=\u00a05.6, 95% CI [0.22, 10.98]).ConclusionsConsidering the lack of clinical efficacy, combined with the significant association with serious adverse events, bapineuzumab should not be used to treat patients with mild to moderate AD. Future studies should investigate the effect of combining bapineuzumab with other therapeutic strategies and reevaluate the efficacy of targeting amyloid \u03b2 proteins in AD therapy.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s12883-017-0850-1", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024950", 
        "issn": [
          "1471-2377"
        ], 
        "name": "BMC Neurology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "17"
      }
    ], 
    "keywords": [
      "Disease Assessment Scale", 
      "adverse events", 
      "risk ratio", 
      "serious treatment-emergent adverse events", 
      "Alzheimer's disease", 
      "treatment-emergent adverse events", 
      "Mini-Mental State Examination score", 
      "mean difference", 
      "Alzheimer's Disease Assessment Scale", 
      "serious adverse events", 
      "Review Manager software", 
      "progressive memory loss", 
      "cerebrospinal fluid concentrations", 
      "prevalent neurodegenerative condition", 
      "confidence intervals", 
      "State Examination score", 
      "cerebral vasogenic edema", 
      "web-based literature search", 
      "Web of Science", 
      "amyloid \u03b2-protein", 
      "bapineuzumab group", 
      "ADAS-cog11", 
      "placebo group", 
      "Cochrane CENTRAL", 
      "clinical efficacy", 
      "BackgroundAlzheimer\u2019s disease", 
      "vasogenic edema", 
      "eligible records", 
      "clinical trials", 
      "Dementia Scale", 
      "AD therapy", 
      "significant worsening", 
      "moderate AD", 
      "MMSE scores", 
      "Disability Assessment", 
      "gradual impairment", 
      "therapeutic strategies", 
      "neurodegenerative conditions", 
      "bapineuzumab", 
      "systematic review", 
      "Manager software", 
      "tau protein", 
      "significant association", 
      "Assessment Scale", 
      "square test", 
      "fluid concentrations", 
      "cognitive function", 
      "memory loss", 
      "literature search", 
      "disease", 
      "monoclonal antibodies", 
      "Chi-square", 
      "effect estimates", 
      "efficacy", 
      "patients", 
      "\u03b2-protein", 
      "examination scores", 
      "baseline", 
      "trials", 
      "relevant keywords", 
      "future studies", 
      "scores", 
      "safety", 
      "EMBASE", 
      "edema", 
      "group", 
      "terms of changes", 
      "therapy", 
      "PubMed", 
      "worsening", 
      "MethodsWe", 
      "doses", 
      "dose", 
      "impairment", 
      "neurotoxic", 
      "protein", 
      "brain", 
      "antibodies", 
      "clearance", 
      "Ovid", 
      "EBSCO", 
      "Scopus", 
      "risk", 
      "association", 
      "events", 
      "review", 
      "changes", 
      "interval", 
      "assessment", 
      "differences", 
      "records", 
      "scale", 
      "study", 
      "Central", 
      "lack", 
      "test", 
      "loss", 
      "effect", 
      "heterogeneity", 
      "concentration", 
      "keywords", 
      "search", 
      "DAD", 
      "function", 
      "data", 
      "strategies", 
      "ratio", 
      "Web", 
      "AD", 
      "terms", 
      "conditions", 
      "estimates", 
      "science", 
      "software"
    ], 
    "name": "Bapineuzumab for mild to moderate Alzheimer\u2019s disease: a meta-analysis of randomized controlled trials", 
    "pagination": "66", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1084512801"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12883-017-0850-1"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28376794"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12883-017-0850-1", 
      "https://app.dimensions.ai/details/publication/pub.1084512801"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T21:01", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_725.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s12883-017-0850-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12883-017-0850-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12883-017-0850-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12883-017-0850-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12883-017-0850-1'


 

This table displays all metadata directly associated to this object as RDF triples.

259 TRIPLES      21 PREDICATES      146 URIs      136 LITERALS      12 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12883-017-0850-1 schema:about N80963b37b9224a20a67960a79c235d41
2 Nadbfa14c234148e6a5a26a41941a3cd2
3 Naf1f12bda6df4caeade6602a76c3f57a
4 Nb841ba0b9be74dcb8e2f44695e621d71
5 Ndfc0d6a4a8c244c8852beddfa2d6383d
6 anzsrc-for:11
7 anzsrc-for:1109
8 schema:author N635ab233c0f147adbe324409bbf38336
9 schema:citation sg:pub.10.1038/78682
10 sg:pub.10.1038/nm1782
11 schema:datePublished 2017-04-04
12 schema:datePublishedReg 2017-04-04
13 schema:description BackgroundAlzheimer’s disease (AD) is a globally prevalent neurodegenerative condition, clinically characterized by progressive memory loss and gradual impairment of cognitive functions. Bapineuzumab is a fully humanized monoclonal antibody that binds to neurotoxic amyloid proteins in the brain, enhancing their clearance. We performed this systematic review and meta-analysis to evaluate the safety and efficacy of bapineuzumab in patients with mild to moderate Alzheimer’s disease.MethodsWe performed a web-based literature search of PubMed, Ovid, EBSCO, Scopus, Embase, Cochrane CENTRAL, and web of science using the relevant keywords. Data were extracted from eligible records and pooled as mean difference (MD) or risk ratio (RR) values with their 95% confidence interval (CI), using Review Manager software (version 5.3 for windows). Heterogeneity was measured by Chi-square and I-square tests.ResultThe pooled effect estimate from six randomized clinical trials (n = 2380) showed that bapineuzumab significantly reduced the cerebrospinal fluid concentration of phosphorylated tau proteins (Standardized MD = −5.53, 95% CI [−8.29, −2.76]). However, the bapineuzumab group was not superior to the placebo group in terms of change from baseline in Alzheimer’s disease assessment scale (ADAS)-Cog11 (MD = 0.14, 95% CI [−0.72, 0.99]), disability assessment for dementia (DAD) scale (MD = 1.35, 95% CI [−1.74, 4.43]), and mini-mental state examination (MMSE) scores (MD = 0.08, 95% CI [−0.31, 0.47]). Regarding safety, bapineuzumab increased the risk of serious treatment-emergent adverse events (RR = 1.18, 95% CI [1.02, 1.37]) and cerebral vasogenic edema (RR = 40.88, 95% CI [11.94, 135.95]). All bapineuzumab doses (0.15, 0.5, 1, and 2 mg/kg) were similar to placebo in terms of change from baseline in ADAS-cog11, DAD, and MMSE scores, except for the 0.15 mg/kg dose, which caused a significant worsening on the ADAS-cog11 scale (MD = 5.6, 95% CI [0.22, 10.98]).ConclusionsConsidering the lack of clinical efficacy, combined with the significant association with serious adverse events, bapineuzumab should not be used to treat patients with mild to moderate AD. Future studies should investigate the effect of combining bapineuzumab with other therapeutic strategies and reevaluate the efficacy of targeting amyloid β proteins in AD therapy.
14 schema:genre article
15 schema:isAccessibleForFree true
16 schema:isPartOf N9b3cdca3567140449bf2e794f8c969b1
17 Ndb9d8ee56ab345a2ade321434896620b
18 sg:journal.1024950
19 schema:keywords AD
20 AD therapy
21 ADAS-cog11
22 Alzheimer's Disease Assessment Scale
23 Alzheimer's disease
24 Assessment Scale
25 BackgroundAlzheimer’s disease
26 Central
27 Chi-square
28 Cochrane CENTRAL
29 DAD
30 Dementia Scale
31 Disability Assessment
32 Disease Assessment Scale
33 EBSCO
34 EMBASE
35 MMSE scores
36 Manager software
37 MethodsWe
38 Mini-Mental State Examination score
39 Ovid
40 PubMed
41 Review Manager software
42 Scopus
43 State Examination score
44 Web
45 Web of Science
46 adverse events
47 amyloid β-protein
48 antibodies
49 assessment
50 association
51 bapineuzumab
52 bapineuzumab group
53 baseline
54 brain
55 cerebral vasogenic edema
56 cerebrospinal fluid concentrations
57 changes
58 clearance
59 clinical efficacy
60 clinical trials
61 cognitive function
62 concentration
63 conditions
64 confidence intervals
65 data
66 differences
67 disease
68 dose
69 doses
70 edema
71 effect
72 effect estimates
73 efficacy
74 eligible records
75 estimates
76 events
77 examination scores
78 fluid concentrations
79 function
80 future studies
81 gradual impairment
82 group
83 heterogeneity
84 impairment
85 interval
86 keywords
87 lack
88 literature search
89 loss
90 mean difference
91 memory loss
92 moderate AD
93 monoclonal antibodies
94 neurodegenerative conditions
95 neurotoxic
96 patients
97 placebo group
98 prevalent neurodegenerative condition
99 progressive memory loss
100 protein
101 ratio
102 records
103 relevant keywords
104 review
105 risk
106 risk ratio
107 safety
108 scale
109 science
110 scores
111 search
112 serious adverse events
113 serious treatment-emergent adverse events
114 significant association
115 significant worsening
116 software
117 square test
118 strategies
119 study
120 systematic review
121 tau protein
122 terms
123 terms of changes
124 test
125 therapeutic strategies
126 therapy
127 treatment-emergent adverse events
128 trials
129 vasogenic edema
130 web-based literature search
131 worsening
132 β-protein
133 schema:name Bapineuzumab for mild to moderate Alzheimer’s disease: a meta-analysis of randomized controlled trials
134 schema:pagination 66
135 schema:productId N379e09358a9640b9a5338724e1e5f32a
136 N65ef4d9959f743a28553657c38fa7324
137 N67074fee912a4da1b7886f77918fe302
138 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084512801
139 https://doi.org/10.1186/s12883-017-0850-1
140 schema:sdDatePublished 2022-11-24T21:01
141 schema:sdLicense https://scigraph.springernature.com/explorer/license/
142 schema:sdPublisher Nf02f03abf0c84f75a5d7bef36b5216f9
143 schema:url https://doi.org/10.1186/s12883-017-0850-1
144 sgo:license sg:explorer/license/
145 sgo:sdDataset articles
146 rdf:type schema:ScholarlyArticle
147 N15c66ca14301438a81a02a6d52c38454 rdf:first sg:person.012124155033.53
148 rdf:rest N79a2956d13194eacbbfb1fc3db5819e8
149 N36f7b96dc6df4cfb89c0745745a557db schema:affiliation grid-institutes:grid.31451.32
150 schema:familyName Fouda
151 schema:givenName Rana
152 rdf:type schema:Person
153 N379e09358a9640b9a5338724e1e5f32a schema:name doi
154 schema:value 10.1186/s12883-017-0850-1
155 rdf:type schema:PropertyValue
156 N635ab233c0f147adbe324409bbf38336 rdf:first sg:person.01071425357.16
157 rdf:rest Ne4b6afd215f04a96bd412f83e24603aa
158 N65ef4d9959f743a28553657c38fa7324 schema:name dimensions_id
159 schema:value pub.1084512801
160 rdf:type schema:PropertyValue
161 N67074fee912a4da1b7886f77918fe302 schema:name pubmed_id
162 schema:value 28376794
163 rdf:type schema:PropertyValue
164 N79a2956d13194eacbbfb1fc3db5819e8 rdf:first Nbe4f37afce4047f9891a612f0e5242c8
165 rdf:rest Ne5e895c2148945e0b7903f8e0e9a0e00
166 N80963b37b9224a20a67960a79c235d41 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Outcome Assessment, Health Care
168 rdf:type schema:DefinedTerm
169 N9b3cdca3567140449bf2e794f8c969b1 schema:issueNumber 1
170 rdf:type schema:PublicationIssue
171 Nadbfa14c234148e6a5a26a41941a3cd2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Alzheimer Disease
173 rdf:type schema:DefinedTerm
174 Naf1f12bda6df4caeade6602a76c3f57a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Humans
176 rdf:type schema:DefinedTerm
177 Nb2aad354d06b47d68f4414e9280c8175 rdf:first sg:person.015112057033.82
178 rdf:rest rdf:nil
179 Nb841ba0b9be74dcb8e2f44695e621d71 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Randomized Controlled Trials as Topic
181 rdf:type schema:DefinedTerm
182 Nbe4f37afce4047f9891a612f0e5242c8 schema:affiliation grid-institutes:grid.411660.4
183 schema:familyName Salama
184 schema:givenName Reham
185 rdf:type schema:Person
186 Ndb9d8ee56ab345a2ade321434896620b schema:volumeNumber 17
187 rdf:type schema:PublicationVolume
188 Ndfc0d6a4a8c244c8852beddfa2d6383d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Antibodies, Monoclonal, Humanized
190 rdf:type schema:DefinedTerm
191 Ne4b6afd215f04a96bd412f83e24603aa rdf:first sg:person.013206550571.50
192 rdf:rest N15c66ca14301438a81a02a6d52c38454
193 Ne5e895c2148945e0b7903f8e0e9a0e00 rdf:first sg:person.01365162611.97
194 rdf:rest Nf31612b8e2a84361975286808fcdac5f
195 Nf02f03abf0c84f75a5d7bef36b5216f9 schema:name Springer Nature - SN SciGraph project
196 rdf:type schema:Organization
197 Nf31612b8e2a84361975286808fcdac5f rdf:first N36f7b96dc6df4cfb89c0745745a557db
198 rdf:rest Nb2aad354d06b47d68f4414e9280c8175
199 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
200 schema:name Medical and Health Sciences
201 rdf:type schema:DefinedTerm
202 anzsrc-for:1109 schema:inDefinedTermSet anzsrc-for:
203 schema:name Neurosciences
204 rdf:type schema:DefinedTerm
205 sg:journal.1024950 schema:issn 1471-2377
206 schema:name BMC Neurology
207 schema:publisher Springer Nature
208 rdf:type schema:Periodical
209 sg:person.01071425357.16 schema:affiliation grid-institutes:None
210 schema:familyName Abushouk
211 schema:givenName Abdelrahman Ibrahim
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01071425357.16
213 rdf:type schema:Person
214 sg:person.012124155033.53 schema:affiliation grid-institutes:grid.412258.8
215 schema:familyName Aglan
216 schema:givenName Amro
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012124155033.53
218 rdf:type schema:Person
219 sg:person.013206550571.50 schema:affiliation grid-institutes:grid.411303.4
220 schema:familyName Elmaraezy
221 schema:givenName Ahmed
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013206550571.50
223 rdf:type schema:Person
224 sg:person.01365162611.97 schema:affiliation grid-institutes:grid.31451.32
225 schema:familyName Fouda
226 schema:givenName Samar
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01365162611.97
228 rdf:type schema:Person
229 sg:person.015112057033.82 schema:affiliation grid-institutes:grid.8192.2
230 schema:familyName AlSafadi
231 schema:givenName Ammar M.
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015112057033.82
233 rdf:type schema:Person
234 sg:pub.10.1038/78682 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039144595
235 https://doi.org/10.1038/78682
236 rdf:type schema:CreativeWork
237 sg:pub.10.1038/nm1782 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013028078
238 https://doi.org/10.1038/nm1782
239 rdf:type schema:CreativeWork
240 grid-institutes:None schema:alternateName NovaMed Medical Research Association, Cairo, Egypt
241 schema:name Faculty of Medicine, Ain Shams University, Cairo, Egypt
242 NovaMed Medical Research Association, Cairo, Egypt
243 rdf:type schema:Organization
244 grid-institutes:grid.31451.32 schema:alternateName Faculty of Medicine, Zagazig University, Elsharkia, Egypt
245 schema:name Faculty of Medicine, Zagazig University, Elsharkia, Egypt
246 rdf:type schema:Organization
247 grid-institutes:grid.411303.4 schema:alternateName Faculty of Medicine, Al-Azhar University, Cairo, Egypt
248 schema:name Faculty of Medicine, Al-Azhar University, Cairo, Egypt
249 NovaMed Medical Research Association, Cairo, Egypt
250 rdf:type schema:Organization
251 grid-institutes:grid.411660.4 schema:alternateName Faculty of Medicine, Benha University, Qaluobia, Egypt
252 schema:name Faculty of Medicine, Benha University, Qaluobia, Egypt
253 rdf:type schema:Organization
254 grid-institutes:grid.412258.8 schema:alternateName Faculty of Medicine, Tanta University, Tanta, Egypt
255 schema:name Faculty of Medicine, Tanta University, Tanta, Egypt
256 rdf:type schema:Organization
257 grid-institutes:grid.8192.2 schema:alternateName Faculty of Medicine, Damascus University, Damascus, Syria
258 schema:name Faculty of Medicine, Damascus University, Damascus, Syria
259 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...